Measuring a biomarker in patients with chronic mesenteric ischemia
Intestinal Ischemia Biomarker and Quality of Life of the Patients With Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome
This study is testing if measuring a specific protein in the blood can help doctors better understand and treat patients with chronic mesenteric ischemia and related conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo, Oslo) |
| Trial ID | NCT06468774 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare plasma levels of Alpha glutathione S transferase (Alpha GST) in patients diagnosed with chronic mesenteric ischemia (CMI) and median arcuate ligament syndrome (MALS) against individuals with Morbus Crohn, gallstone disease, and healthy controls. The study will include patients scheduled for surgical treatment and will assess changes in Alpha GST levels pre- and post-treatment. Additionally, it will evaluate the health-related quality of life of participants. The goal is to identify a reliable biomarker for intestinal ischemia that could aid in diagnosis and treatment decisions.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with a diagnosis of CMI or MALS who are scheduled for surgical intervention.
Not a fit: Patients under 18 years or those who have not provided informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a reliable biomarker for diagnosing chronic mesenteric ischemia and median arcuate ligament syndrome, improving patient outcomes.
How similar studies have performed: Previous studies have indicated raised levels of Alpha GST in patients with CMI and MALS, but this study aims to provide a more robust comparison with control groups.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Above 18 years and has given informed written consent for treatment and study participation For the patient groups : Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment. Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment. For the control group: Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy. Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound. Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound. Exclusion Criteria: Age less than 18 years Has nor given written consent. \-
Where this trial is running
Oslo, Oslo
- Department of vascular surgery, Oslo University Hospital — Oslo, Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Syed Sajid Hussain Kazmi, MD, PhD — Department of vascular surgery, Oslo University Hospital
- Study coordinator: Syed Sajid Hussain Kazmi, MD, PhD
- Email: sshkazmi@gmail.com
- Phone: 4792468309
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.